icotrokinra

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

By afschroeder • October 30, 2026

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

McInnes IB, Stein Gold L, Bissonnette R, Lebwohl MG, Reyes-Servin O, Cafone J, Yang YW, Chakravarty SD, Iaconangelo C, Li S, Shagroni T, Lozenski K,[...]

By afschroeder • October 21, 2026